Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis.
Gurion R, Gafter-Gvili A, Vidal L, Leader A, Ram R, Shacham-Abulafia A, Paul M, Ben-Bassat I, Shpilberg O, Raanani P. Haematologica. 2013 Jan; 98(1):95-102. Epub 2012 Aug 8.